

# StÃ©phane Depil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/483886/publications.pdf>

Version: 2024-02-01

93  
papers

3,789  
citations

172457

29  
h-index

133252

59  
g-index

102  
all docs

102  
docs citations

102  
times ranked

6938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabj3671.	10.3	38
2	Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. <i>European Journal of Cancer</i> , 2022, 171, 96-105.	2.8	3
3	<scp>HERVs</scp> characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. <i>American Journal of Hematology</i> , 2022, 97, 1200-1214.	4.1	8
4	691â€¦Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy. , 2021, 9, A719-A719.		0
5	â€œOff-the-shelfâ€™™ allogeneic CAR T cells: development and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 185-199.	46.4	632
6	Toward â€œoffâ€™theâ€™shelfâ€™ allogeneic CAR T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e86.	0.9	20
7	Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers. <i>Cancers</i> , 2020, 12, 610.	3.7	44
8	Abstract LB-078: Effect of a combined immune checkpoint inhibitor and mechanical focused ultrasound treatment on intratumoral immune response in a MC38 preclinical model. , 2020, , .		0
9	Modulation of chimeric antigen receptor surface expression by a small molecule switch. <i>BMC Biotechnology</i> , 2019, 19, 44.	3.3	87
10	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. <i>Annals of Oncology</i> , 2019, 30, v159.	1.2	13
11	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	49
12	Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. <i>Nature Communications</i> , 2019, 10, 5100.	12.8	42
13	Cold Tumors: A Therapeutic Challenge for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 168.	4.8	733
14	Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity. <i>Cancer Research</i> , 2019, 79, 3651-3661.	0.9	62
15	Granulocyteâ€™macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. <i>Journal of Biological Chemistry</i> , 2019, 294, 5430-5437.	3.4	114
16	Neoepitopes-based vaccines: challenges and perspectives. <i>European Journal of Cancer</i> , 2019, 108, 55-60.	2.8	20
17	Cancer vaccines: whatâ€™™s next?. <i>Oncotarget</i> , 2019, 10, 3985-3987.	1.8	2
18	CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. <i>Annals of Oncology</i> , 2018, 29, x9.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Abstract 4934: Immunostimulatory and oncolytic properties of rotavirus can overcome resistance to immune checkpoint blockade therapy. , 2018, , .		0
20	Pattern recognition receptors: immune targets to enhance cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1756-1766.	1.2	123
21	Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. <i>Oncotarget</i> , 2017, 8, 56210-56227.	1.8	17
22	Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma. <i>Gene</i> , 2016, 580, 134-143.	2.2	9
23	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers. <i>Cancer Cell</i> , 2016, 29, 173-185.	16.8	80
24	Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 177-187.	6.4	67
25	HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 81-89.	2.5	19
26	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <i>Investigational New Drugs</i> , 2015, 33, 423-431.	2.6	33
27	TIPIN depletion leads to apoptosis in breast cancer cells. <i>Molecular Oncology</i> , 2015, 9, 1580-1598.	4.6	19
28	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14139-14152.	1.8	22
29	Abstract 2921: Preclinical characteristics of NP137, a first-in-class monoclonal antibody directed against netrin-1 and inducing dependence receptors-mediated cell death. , 2015, , .		3
30	Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. <i>Cell Death and Disease</i> , 2014, 5, e1423-e1423.	6.3	36
31	368 NP137, the first humanized monoclonal antibody directed against netrin-1, exhibits antitumor activity by inducing dependence receptors-mediated cell death. <i>European Journal of Cancer</i> , 2014, 50, 118-119.	2.8	0
32	Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2014, 166, 875-890.	2.5	49
33	Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts. <i>PLoS ONE</i> , 2014, 9, e80836.	2.5	38
34	Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts. <i>PLoS ONE</i> , 2014, 9, e91325.	2.5	34
35	Abstract 2764: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target. , 2014, , .		1
36	Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		3,5

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. <i>European Journal of Cancer</i> , 2013, 49, 2791-2797.	2.8	29
38	Decoding and unlocking the BCL-2 dependency of cancer cells. <i>Nature Reviews Cancer</i> , 2013, 13, 455-465.	28.4	194
39	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low <i>Xist</i> Expression. <i>Clinical Cancer Research</i> , 2013, 19, 6520-6531.	7.0	122
40	Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2013, 73, 813-823.	0.9	182
41	S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1749-1762.	4.1	78
42	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. <i>Cell Death and Disease</i> , 2013, 4, e738-e738.	6.3	30
43	TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e63712.	2.5	120
44	Abstract 4373: LRP5: a potential therapeutic target in triple-negative breast cancer.. , 2013, , .		1
45	Abstract 1013: Treatment of EBV-positive nasopharyngeal carcinoma xenografts with the HDAC-inhibitor Abexinostat: synergy with cis-platinum.. , 2013, , .		0
46	Abstract C219: Novel MET/FGFR/AXL kinase inhibitor S49076 exerts radiosensitizing activity in vitro and in vivo.. , 2013, , .		0
47	Abstract C65: First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.. , 2013, , .		0
48	Abstract B233: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target.. , 2013, , .		0
49	Abstract OT1-4-05: Phase I dose-escalation study of oral administration of abexinostat (S 78454,) Tj ETQq1 1 0.784314 rgBT /Overloc .		0
50	EBV Latency II-derived Peptides Induce A Specific CD4+ Cytotoxic T-cell Activity and Not A CD4+ Regulatory T-cell Response. <i>Journal of Immunotherapy</i> , 2012, 35, 254-266.	2.4	18
51	576 Integrative Approaches for the Identification of Therapeutic Targets in Basal-like Breast Cancer From Multi-level Molecular Data. <i>European Journal of Cancer</i> , 2012, 48, S137.	2.8	0
52	777 Antitumor Activity of the New Bcl-2/Bcl-xl Inhibitor S44563 in Primary Human Uveal Melanoma Xenografts. <i>European Journal of Cancer</i> , 2012, 48, S185.	2.8	0
53	829 Polo-like Kinase 1 â€“ a Potential Therapeutic Target for the Management of Patients With Triple Negative Breast Cancer. <i>European Journal of Cancer</i> , 2012, 48, S199.	2.8	0
54	947 Molecular Profiling of Residual Tumor Cells After Various Chemotherapies Shows Distinct Gene Expression Patterns in Patient-derived Breast Cancer Xenografts. <i>European Journal of Cancer</i> , 2012, 48, S228.	2.8	0

#	ARTICLE	IF	CITATIONS
55	524 LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer. <i>European Journal of Cancer</i> , 2012, 48, 161-162.	2.8	0
56	63 IN VIVO RADIOSENSITIZER EFFECT OF THE HDAC INHIBITOR S78454 ON ORTHOTOPIC HUMAN GLIOBLASTOMA. <i>Radiotherapy and Oncology</i> , 2012, 102, S22.	0.6	0
57	Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. <i>Trends in Biotechnology</i> , 2012, 30, 575-582.	9.3	94
58	Abstract 3000: Molecular profiling of residual tumor cells after various chemotherapies shows distinct gene expression patterns in patient-derived breast cancer xenografts. <i>Cancer Research</i> , 2012, 72, 3000-3000.	0.9	5
59	Abstract 5130: Integrative approaches for the identification of therapeutic targets in basal like breast cancer from multi-level molecular data. , 2012, , .		4
60	Abstract 848: Preclinical antitumor activity of S 49076, a novel MET / AXL / FGFR kinase inhibitor and molecular stratification for tumor sensitivity. , 2012, , .		0
61	Abstract 2782: Bcl-2 selective antagonists show antitumor activity without dose limiting platelet toxicity. , 2012, , .		0
62	Abstract 4702: Antitumor activity of a novel histone deacetylase inhibitor S78454 in EBV-associated nasopharyngeal carcinoma. , 2012, , .		0
63	Abstract 2022: P53-dependent thrombocytopenia induced by the histone deacetylase inhibitor S78454. , 2012, , .		0
64	Abstract 4704: Effects of the HDAC inhibitor S78454/PCI-24781 on ER signalling in ER $\pm$ -positive antiestrogen-sensitive and -resistant breast cancer cells. , 2012, , .		0
65	Abstract 4891: Radiation enhances the efficacy of Bcl-2 and Bcl-XLinhibition in small cell lung cancer: A new concept of using radiation for targeted therapy through contextual oncogene addiction. , 2012, , .		0
66	Abstract 2938: Polo-like kinase 1: a potential therapeutic target for the management of patients with triple negative breast cancer. , 2012, , .		0
67	Antitumor evaluation of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts. <i>Acta Ophthalmologica</i> , 2012, 90, 0-0.	1.1	0
68	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylase (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. <i>Blood</i> , 2012, 120, 3643-3643.	1.4	2
69	Abstract B85: In vivo radiosensitizer effect of the HDAC inhibitor S78454 on orthotopic human glioblastoma.. , 2011, , .		0
70	Abstract A57: Targeting breast cancer stem cells by inducing cell differentiation using histone deacetylase inhibitor S78454.. , 2011, , .		0
71	Abstract A240: Preclinical molecular stratification of human tumors sensitive or resistant to S 49076, a novel MET/FGFR/AXL kinase inhibitor.. , 2011, , .		0
72	Abstract A238: S 49076, a novel, potent, MET/FGFR/AXL kinase inhibitor with wide antitumor activity.. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I., 2011, .		0
74	Abstract A107: S 78454/PCI-24781, a novel HDAC inhibitor, targets the DNA damage response leading to radiosensitization of both normoxic and hypoxic NSCLC cell lines., 2011, .		0
75	Abstract B217: Antitumor activity of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts., 2011, .		0
76	Phase II study of gemcitabine+dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. <i>Annals of Oncology</i> , 2007, 18, 370-375.	1.2	38
77	Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies. <i>Journal of Immunotherapy</i> , 2007, 30, 215-226.	2.4	24
78	Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. <i>Vaccine</i> , 2007, 25, 5927-5937.	3.8	19
79	Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. <i>Experimental Hematology</i> , 2007, 35, 861-871.	0.4	16
80	Peptide-binding assays and HLA II transgenic $\beta_2\mu^0$ mice are consistent and complementary tools for identifying HLA II-restricted peptides. <i>Vaccine</i> , 2006, 24, 2225-2229.	3.8	11
81	A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. <i>Leukemia</i> , 2006, 20, 1557-1565.	7.2	52
82	Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. <i>Leukemia Research</i> , 2005, 29, 665-671.	0.8	11
83	Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 706-707.	2.5	6
84	Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have a human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 841-849.	1.3	4
85	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2481-2484.	1.3	11
86	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2004, 33, 531-534.	2.4	48
87	A case of refractory anemia with 17p <sup>+</sup> syndrome following azathioprine treatment for heart transplantation. <i>Leukemia</i> , 2004, 18, 878-878.	7.2	8
88	Efficient generation of antileukemic autologous T cells by short-term culture and $\gamma$ -irradiation of myeloid leukemic cells. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 793-8.	4.2	8
89	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. <i>Transplantation</i> , 2004, 78, 1697-1701.	1.0	64
90	Chemotherapy increases transgene expression in leukemic cells. <i>Journal of Gene Medicine</i> , 2003, 5, 852-859.	2.8	1

#	ARTICLE	IF	CITATIONS
91	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. <i>Leukemia</i> , 2003, 17, 1678-1679.	7.2	20
92	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. <i>Leukemia and Lymphoma</i> , 2002, 43, 1819-1822.	1.3	7
93	Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. <i>Leukemia</i> , 2002, 16, 254-259.	7.2	121